null

Tiragolumab Biosimilar (Anti-TIGIT) Antibody (HDBS0026)

SKU:
HDBS0026
Antibody Type:
Biosimilar Reference Antibody
Applications:
IHC
FC
Drug Development
Pharmacokinetics
Disease Area:
Cancer
Protein:
TIGIT
Reactivity:
Human
Host Species:
Humanized
Isotype:
IgG1
€399

Description

system_update_altDatasheet

Tiragolumab (Anti-TIGIT) Biosimilar Antibody (HDBS0026)

The Anti-TIGIT (Tiragolumab Biosimilar) Monoclonal Antibody (HDbs0026) is a cutting-edge tool for researchers studying T-cell immunoreceptor with Ig and ITIM domains (TIGIT) in immune regulation. This monoclonal antibody, produced through biosimilar technology, provides high specificity and sensitivity for detecting TIGIT in human samples, making it a valuable asset for immunology and oncology studies.TIGIT is a co-inhibitory receptor, known for its role in dampening immune responses and promoting immune tolerance. Its dysregulation has been linked to various diseases, including cancer and autoimmune disorders.

By targeting TIGIT, researchers can gain insights into immune modulation and potentially develop novel therapeutic strategies for combating these diseases.This antibody offers researchers a reliable tool for investigating TIGIT expression and function, particularly in the context of immune checkpoint pathways. Its high reactivity and validation for use in various applications, such as flow cytometry and immunohistochemistry, make it a versatile option for researchers seeking to delve deeper into the intricate mechanisms of immune regulation and potential therapeutic interventions.